Paper Details

  1. Home
  2. Paper Details

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

Author: AngiolilloDominick J, CurzenNicholas, EffronMark B, GurbelPaul, JakubowskiJoseph A, LiWei, LipkinFred, TrenkDietmar, VaitkusPaul, ZettlerMarjorie

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Switching from ticagrelor to prasugrel therapy was associated with an increase in platelet reactivity, which was partially mitigated by the administration of a loading dose.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The goal of this study was to evaluate the pharmacodynamic effects of switching patients from ticagrelor to prasugrel. BACKGROUND: Clinicians may need to switch between more potent P2Y12 inhibitors because of adverse effects or switch to the use of a once-daily dosing regimen due to com...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jacc.2013.11.032

データ提供：米国国立医学図書館（NLM）

Switching Antiplatelet Therapy: A Balancing Act for Cardiovascular Health

The field of [cardiology] is constantly seeking to optimize [antiplatelet therapy] for [patients with stable coronary artery disease]. This research delves into the [pharmacodynamic effects] of [switching from ticagrelor to prasugrel]. Employing a [randomized crossover study], the researchers investigated the [platelet reactivity] in [patients with stable coronary artery disease] who [switched from ticagrelor to prasugrel]. Their findings reveal that [switching from ticagrelor to prasugrel is associated with an increase in platelet reactivity] that can be [partially mitigated by the administration of a prasugrel loading dose]. This discovery highlights the importance of [careful monitoring and individualized treatment plans] when [switching between antiplatelet agents].

Navigating the Sands of Antiplatelet Therapy: Choosing the Right Path

The study's results demonstrate the need for [a nuanced approach] to [antiplatelet therapy switching]. It's like navigating a shifting desert landscape—a careful and calculated approach is crucial for maintaining a safe and effective course. This research suggests that [switching from ticagrelor to prasugrel should be undertaken with caution] and that [patients should be closely monitored] for [changes in platelet reactivity].

A Cautious Approach to Antiplatelet Therapy Switching

This research underscores the importance of [individualized treatment plans] and [close monitoring] when [switching between antiplatelet agents]. It's crucial to [consider patient-specific factors] such as [risk of bleeding, compliance with medication, and individual responses to different drugs]. It's like navigating a vast desert—the path to optimal cardiovascular health may vary depending on the individual traveler.

Dr.Camel's Conclusion

This research reminds us that the journey to cardiovascular health is a complex one, requiring a deep understanding of the [mechanisms of antiplatelet therapy] and the [potential impact of drug switching]. It's like navigating a vast desert—a careful and informed approach is essential for finding the oasis of optimal health.

Date :
  1. Date Completed 2014-06-10
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24333493

DOI: Digital Object Identifier

10.1016/j.jacc.2013.11.032

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.